Rhea-AI Summary
Axonics, Inc. (Nasdaq: AXNX) reported positive first quarter 2024 financial results with a 29% revenue growth year over year. The company saw increases in revenue for sacral neuromodulation and Bulkamid products, achieving a record gross margin of 75.8%. Operating expenses included acquisition-related costs related to the Boston Scientific merger, leading to a net loss of $19.1 million. Adjusted EBITDA improved to $3.0 million. Cash, cash equivalents, short-term investments, and restricted cash totaled $349 million as of March 31, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
-
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.26%
Tags
-
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.01%
Tags
-
News
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.01%
Tags
-
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
-
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.18%
Tags
-
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.48%
Tags
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.48%
Tags
FAQ
What is the current stock price of Axonex AI Group (AXNX)?
Axonex AI Group (AXNX) last closed at $0.4712.
What is the market cap of Axonex AI Group (AXNX)?
The market cap of Axonex AI Group (AXNX) is approximately $7.0M.